These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25705005)

  • 1. A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study.
    Naganuma T; Latib A; Sgueglia GA; Menozzi A; Castriota F; Micari A; Cremonesi A; De Felice F; Marchese A; Tespili M; Presbitero P; Panoulas VF; Buffoli F; Tamburino C; Varbella F; Colombo A
    Int J Cardiol; 2015 Apr; 184():17-21. PubMed ID: 25705005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study.
    Latib A; Colombo A; Castriota F; Micari A; Cremonesi A; De Felice F; Marchese A; Tespili M; Presbitero P; Sgueglia GA; Buffoli F; Tamburino C; Varbella F; Menozzi A
    J Am Coll Cardiol; 2012 Dec; 60(24):2473-80. PubMed ID: 23158530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients - results from the BELLO (balloon elution and late loss optimization) trial.
    Giannini F; Latib A; Jabbour RJ; Costopoulos C; Chieffo A; Carlino M; Montorfano M; Menozzi A; Castriota F; Micari A; Cremonesi A; De Felice F; Marchese A; Tespili M; Presbitero P; Sgueglia GA; Buffoli F; Tamburino C; Varbella F; Colombo A
    Cardiovasc Revasc Med; 2017; 18(1):4-9. PubMed ID: 28011243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A propensity score matched comparative study between paclitaxel-coated balloon and everolimus-eluting stents for the treatment of small coronary vessels.
    Giannini F; Latib A; Ancona MB; Costopoulos C; Ruparelia N; Menozzi A; Castriota F; Micari A; Cremonesi A; De Felice F; Marchese A; Tespili M; Presbitero P; Sgueglia GA; Buffoli F; Tamburino C; Varbella F; Colombo A
    Catheter Cardiovasc Interv; 2017 Sep; 90(3):380-386. PubMed ID: 28109036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
    JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes.
    Belkacemi A; Agostoni P; Nathoe HM; Voskuil M; Shao C; Van Belle E; Wildbergh T; Politi L; Doevendans PA; Sangiorgi GM; Stella PR
    J Am Coll Cardiol; 2012 Jun; 59(25):2327-37. PubMed ID: 22503057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
    Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary percutaneous coronary intervention by drug-eluting balloon angioplasty: the nonrandomized fourth arm of the DEB-AMI (drug-eluting balloon in ST-segment elevation myocardial infarction) trial.
    Nijhoff F; Agostoni P; Belkacemi A; Nathoe HM; Voskuil M; Samim M; Doevendans PA; Stella PR
    Catheter Cardiovasc Interv; 2015 Oct; 86 Suppl 1():S34-44. PubMed ID: 26119971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
    Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
    JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial.
    Togni M; Eber S; Widmer J; Billinger M; Wenaweser P; Cook S; Vogel R; Seiler C; Eberli FR; Maier W; Corti R; Roffi M; Lüscher TF; Garachemani A; Hess OM; Wandel S; Meier B; Jüni P; Windecker S
    J Am Coll Cardiol; 2007 Sep; 50(12):1123-31. PubMed ID: 17868802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.